The researchers found that from baseline to week 26, the reductions in HbA1c were comparable for Gla-300 and Gla-100 in the overall population and for participants aged ≥75 years. HealthDay News — For ...
These second-generation basal insulin analogs, Gla-300 and IDeg-100, also had similar safety profiles, investigators found. A new study of second-generation basal insulin analogs shows insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback